Mandela's role in building the continent's largest economy ranks among the South African leader's greatest accomplishments
The USDA's experiment with fewer inspectors worked out well—for meatpackers
Challenges to patents, transparency for demand letters, and litigation fees are crucial
It has cut a deal with the country's top wireless carrier, China Mobile
Rising property values spark a return to lavish renovations
The Bill & Melinda Gates Foundation asked for a better condom design. Here are some of the winners
Its biggest rival in fast fashion, Zara isn't into athletic apparel yet
Northwestern's Kellogg School of Management reclaims the top stop after a two-year absence
Author Laurel Delaney discusses the opportunities and risks for small businesses in a "born global" market of 2.4 billion online consumers
Founder: Dr. John Hadden
VC Investment over the last four quarters: $25 million
IRX Therapeutics is a 40-employee biotech firm developing drugs to restore immune system function, particularly in patients with head and neck cancer. Founded over a decade ago and backed by more than $60 million raised mostly from high-net-worth individuals, the company has reduced headcount by a third and delayed some clinical trials planned for 2009, according to Chief Financial Officer Jeffrey Hwang.
Key to startup success: "In normal times where the capital is available, the difference maker among people with good ideas is sharp execution. There's never a substitute for the ability to attract and retain experienced, qualified people to take advantage of the discovery you've made."